

IMPACT & SUSTAINABILITY REPORT

FY 2023-24



CONTENTS

Message from Somerset Indus	01	Impact Themes	32
Impact & Sustainability at Somerset	03	Accessibility	33
About Somerset	04	Affordability	39
Somerset at a Glance	06	Job Creation	47
Somerset Team	07	Quality & Innovation	51
Pan-India Presence	08	ESG at Somerset	57
Our Impact & ESG Journey	09	ESG at a Glance	58
Investment Strategy	10	ESG Philosophy and Framework Map	59
Financial Summary	12	Resource Footprint	61
Fund Highlights - Media and Recognition	13	Human Capital and Safety	69
Portfolio at a Glance	15	Diversity Equity and Inclusion	73
Portfolio Highlights - Awards and Accreditations	21	Governance and Business Ethics	78
Impact at Somerset	23	CSR & Stakeholder Engagement	81
Impact at a Glance	24	Corporate Social Responsibility	82
Impact by Portfolio Companies	25	Stakeholder Engagement Process	84
Enabling Affordability via Ayushman Bharat and Other State Schemes	27	Looking Forward	85
Impact Assessment, Mapping & Quantification	28	Glossary	86
Impact Framework Map	29	About the Report	88

MESSAGE FROM SOMERSET INDUS



We are pleased to present Somerset's third annual Impact and Sustainability Report, where we share how impact and sustainability are integral to our business. At Somerset, providing accessible, affordable and quality healthcare is not just a goal—it is central to our operations. By investing in underserved regions and ensuring our services reach those covered by government schemes and Below Poverty Line (BPL) patients, we make sure our investments deliver both financial returns and meaningful social impact.

Our approach is straightforward: we invest in small and mid-sized Indian healthcare companies that innovate and improve health outcomes. For us, impact and sustainability are naturally woven into these decisions. Whether through operational support, talent acquisition, or strategic planning, we embed these principles into every step, ensuring our investments are both effective and sustainable.

We align with the UN's Sustainable Development Goals (SDGs) and also adhere to other leading frameworks such as the Global Reporting Initiative (GRI), Global Impact Investing Network (GIIN) and the Sustainability Accounting

Standards Board (SASB). These frameworks help us ensure that our social and environmental contributions are genuine and impactful.

Our focus is on making healthcare more affordable and accessible, driving innovation, creating jobs, and upholding strong corporate social responsibility (CSR). Improving healthcare access and outcomes naturally enhances social well-being and economic growth.

Diversity, equity, and inclusion are also essential to our strategy, reflected in our education initiatives, recruiting practices, and corporate governance. We manage risk effectively through transparency and accountability, ensuring long-term success.

We invite you to explore the full report to see how our journey in impact and sustainability drives our business forward. Thank you for your continued support.

Mayur Sirdesai

Founder & Managing Partner





Somerset was formed in 2011 with the goal of providing growth equity to small and mid-sized enterprises focused on the life sciences and healthcare services space in India. When we looked at the investment opportunities that presented themselves, it became clear to us that the large urban centers in India were well served by pharmaceutical and MedTech products and healthcare services in the form of diagnostic clinics, hospitals, and more specialized services. The real growth investment opportunities were in serving the needs of the Tier II and Tier III markets in India, where the healthcare infrastructure was weak, and the reach of most life sciences companies limited.

The impact of investing in companies focused in these geographies within India in terms of improved access to affordable, quality healthcare is significant. And as investors, when we back entrepreneurs and companies that are focused not just on the quality of the care they deliver, but are also savvy enough to deliver this care at a reasonable profit, our objectives in terms of returns are also met.

This alignment of returns and improvements to access and affordability measures are critical to ensuring that investments continue and benefits remain sustainable.

We have several examples in our portfolio that stand as case studies to validate this theory. Our investment in Krsnaa Diagnostics, a provider of in-vivo diagnostic services with a limited number of diagnostic centers in a few states, helped Krsnaa expand its footprint significantly. Eventually on the backs of the success it demonstrated, Krsnaa raised significant additional capital (including at a public offering) and now has a Pan-India presence and is the largest provider of in vivo diagnostic services in India. During Covid, Krsnaa was able to leverage its footprint and quickly adapt to providing RTPCR diagnostic services pan India. The benefits of these services during Covid were literally life-saving.

Similarly, Somerset was the first to recognize the need for quality affordable hospitals in Tier II and Tier III towns in India. Our investment in Cygnus Hospitals when it was barely USD 6 Mn in revenues and a network of five hospitals centered around the NCR region with a limited entry into Haryana's Tier II towns, has blossomed into a 16 facility strong hospital network with over USD 60 Mn in revenues and a presence

across lesser served areas of NCR, Haryana, Uttar Pradesh and even Jammu and Kashmir. Cygnus also provided us with significant learnings along the way and strengthened our belief in the thesis that quality affordable services can be provided at a reasonable profit and attractive returns on investment.

These investments also taught us that given the price points at which healthcare solutions need to be delivered at in lower tier towns and limited access to qualified resources in these towns, deploying these solutions while leveraging technology is also critical to success. In Krsnaa expansion into many Tier II and Tier III towns would not have been possible without a state-of-the-art hub in Pune that deployed tele-radiology solutions towards diagnosing and reporting on the scans that were electronically transmitted to the hub. Similarly at Cygnus Hospitals, providing patient outreach enabled by apps, healthcare screening camps in smaller towns and in some cases deploying tele-medicine solutions were also critical to the network's success.

Going forward we believe that the plentiful investment opportunities in healthcare and life sciences companies in India will continue, and in fact are likely to get a fillip from the government's recognition that supporting and improving healthcare access to the majority of the population which does not reside in the mega urban centers in India is essential to a developed India. The Ayushman Bharat scheme and its avatars under the various state governments did not exist as a Payor mechanism in India when Somerset began its journey in 2011. We now see Ayushman Bharat as an important catalyst for improving access to healthcare for millions of Indian citizens and we believe that Somerset can continue to have a positive impact towards meeting its goal of delivering sustainable access and affordability solutions at attractive returns to its investors.

Avinash Kenkare

Founder & Managing Partner

IMPACT & SUSTAINABILITY AT SOMERSET

Accessibility Scale

67 Mn

Lives Touched

Affordability

0.3 Mn

Patients treated under Ayushman Bharat and other government schemes

Affordability

USD 227 Mn

(INR 18,843 Mn) Revenue generated directly and indirectly from Ayushman Bharat and other government schemes.

Accessibility Reach

700 of 788

Indian Districts Covered (89%)

Accessibility Depth

0.8 Mn

Customers with life threatening diseases served

The Impact and Sustainability framework of Somerset Indus is aligned to global frameworks such as IRIS+, UN SDGs, SASB, GRI, IFC Performance Standards, ILO, UN PRI and that of other Development Finance Institutions.

The impact, environmental, social and governance aspects are assessed as an integral part of the investment appraisal followed by regular monitoring of the portfolio companies across the investment period

Accessibility- Reach

103 of 112

Aspirational Districts covered¹ in India (92%)

Resource Footprint

~1,800 MWh

Renewable energy consumption

Human Capital

~15,000

Direct and indirect jobs

Governance

100%

Fund II portfolio companies have an Anti-Corruption and Anti-Bribery Policy; & Code of Conduct

Diversity, Equity and Inclusion

~6,000

Women serving in diverse roles

Note: The metrics presented above include all seven (7) active portfolio companies of Fund II and three (3) portfolio companies of Fund I (Krsnaa Diagnostics, Ujala Cygnus, Hexagon Nutrition). The metrics under governance only represent the seven portfolio companies of Fund II.

¹Aspirational Districts are districts in India that are affected by poor socio-economic indicators. They are the most underdeveloped districts of India as identified by NITI Aayog.

ABOUT SOMERSET



Somerset Vision and Mission

Somerset is a private equity firm specializing in healthcare, primarily investing in growth-oriented Indian healthcare companies. Founded in 2011 by Avinash Kenkare and Mayur Sirdesai—both with over 20 years of experience in private equity and the healthcare industry—the firm launched its second fund in 2018, expanding its team with partners Sharad Ladha and Kannan Ramesh, who bring deep expertise in private equity, consulting, insurance, and healthcare delivery.

Over more than a decade, Somerset has invested in companies that deeply penetrate the mass Indian market, particularly where government insurance schemes such as Ayushman Bharat (India's flagship public health insurance scheme implemented by National Health Authority) are the primary payor. This strategy has proven both financially rewarding and impactful.



Vision

To be the leading partner in healthcare across tier II and tier III markets, recognized for our unmatched strategic, operational, and financial expertise in shaping the future of healthcare in India.



Mission

To create sustainable, life-changing impact for all our stakeholders, while ensuring that our strategies are aligned with long-term business fundamentals and global healthcare trends.

To provide quality and affordable healthcare throughout India, particularly in the lower tier markets, Somerset seeks to invest in healthcare delivery products and service platforms managed by seasoned healthcare entrepreneurs. The team invests in Indian healthcare companies and successfully uses the cash to build businesses and boost profitability. The team draws on its successful private equity investment experience, knowledge of healthcare systems, and extensive experience and knowledge of the healthcare industry in India.

With Fund-3, Somerset aims to further extend its reach within more aspirational districts in the mass market of India, expand exports to other low-to-middle-income countries (LMICs) in Asia, Africa, and Latin America, and explore other sub-sectors in healthcare. The fund broadly focuses on government schemes like Ayushman Bharat to enhance healthcare reach, accessibility, and affordability. Somerset Indus Funds (SIH) have institutionalized impact measurement, led by a dedicated Impact/Sustainability/ESG team, ensuring continuous improvement in quantifying and enhancing societal impact, demonstrating the intentionality of impact embedded within Somerset's investment strategy.

Somerset at a Glance

2

Number of Funds

14

Number of Portfolio Companies

USD 83 Mn

Total Capital Invested

3

Number of hospital chains

4

Number of pharma & life sciences groups

4

Number of MedTech companies

1

Number of diagnostic chains

2

Number of companies in other categories (specialty clinics and pharma packaging)



SOMERSET TEAM

**Strong Team
with 100+ Years
of Experience
in Investing and
Healthcare**



Avinash Kenkare
(Founding Partner)



Mayur Sirdesai
(Founding Partner)



Ramesh Kannan
(Partner)



Sharad Ladha
(Partner)

Investment Management



Vaibhav Doshi
(Executive Director)



Abhishek Mudafale
(Investment Principal)



Ashwin Shenoy
(Sr. Investments
Associate)



Dhaval Desai
(Sr. Investments
Associate)



Arundati Khajuria
(Analyst)



Raj Parikh
(Analyst)



Zulfikar Trivedi
(CFO)



Ameya Karulkar
(ESG Manager)




Rahul Jaju
(Sr. Finance and
Operations Associate)



Pranali Redij
(Administration
Executive)

PAN-INDIA PRESENCE



District Level Penetration

1. ~700 of 788 Districts in India covered across Fund I and Fund II (89%)
2. ~103 of the 112 Aspirational Districts in India covered across Fund I and Fund II (92%)

● Somerset Indus Capital Partners

Fund 1 Portfolio Companies

- 📍 Sandor Medicaids
- 📍 Express Clinics
- 📍 Ujala Cygnus
- 📍 Prognosys Medical Systems, Prognosys Healthcare and Chayagraphics Healthcare
- 📍 Krsnaa Diagnostics
- 📍 Browndove Healthcare
- 📍 Hexagon Nutrition

Fund 2 Portfolio Companies

- 📍 Apex Hospitals
- 📍 Genworks Health
- 📍 Globela Pharma
- 📍 Sterling Hospitals
- 📍 Emil Pharmaceutical Industries
- 📍 Natural Biogenex
- 📍 Printmann Offset

Our Impact & ESG Journey

2023-24

- Mapping targets Vs Progress
- Aligning reporting on GRI, SASB and IRIS+ framework

2024-25

Our plan of actions for the year:

- GHG Emission calculations for all portfolio companies
- Launch impact- focused Fund 3, aligned with IMM framework
- Mapping Somerset portfolio performance against SFDR
- Increased focus on gender diversity

2021-22

- 1st Sustainability & Impact report released

2020

- Dedicated ESG Manager onboarded
- KPI for ESG defined and Monitoring started

2022-23


- 2nd Sustainability report released
- Materiality assessment completed
- Aligning with UN's SDGs

2020-21

- E&S Policy adopted
- ESMS Adopted & Linked to Investment process

Investment Strategy

As a healthcare-focused fund, Somerset invests in Indian healthcare companies with growth potential. The investment strategy has evolved from focusing on healthcare facilities, majorly hospitals, through Fund 1, to Pharmaceutical and healthcare equipment through Fund 2. Somerset aims to generate both financial and social returns through its investments, ensuring that each investment contributes to making healthcare more affordable and accessible.




Somerset Indus investment principles integrate impact measurement using IRIS+, aligning with the UN's Sustainable Development Goals (SDGs). These principles guide the strategy, particularly in Tier II and Tier III cities in India, where they foster inclusive economic development and enhance access to healthcare solutions

Impact & ESG in Investment Cycle

Somerset pursues an impact & ESG driven investing philosophy from investment selection through portfolio management and shareholder advocacy to exit management. Integrating impact and ESG considerations into investment choices is critical for identifying risks and opportunities, as well as guaranteeing long-term and sustainable wealth creation for the fund, its portfolio companies, their management and employees. The Fund's ESG and impact strategy is interwoven in all elements of its investing process, from initial investment selection to subsequent value generation and exits, assuring a long-term ownership structure in the future.


Somerset's investment appraisal process is rigorously mapped against global ESG frameworks, ensuring a comprehensive approach to responsible investing. These include OPIM Principles (Operating Principles for Impact Management), IFC Performance Standards (International Finance Corporation Performance Standards), International Labour Organization (ILO) standards, and the Principles for Responsible Investment (PRI).

Investment Appraisal Process




Financial Summary

Fund 1



Fund 1	USD	INR
Gross MOIC	3.64x	4.59x
Gross DPI	2.73x	3.49x

Fund 2



Fund 2	USD	INR
Gross MOIC	1.38x	1.47x
Gross DPI	-	-


1. Somerset Indus Healthcare Fund I Limited is a USD denominated fund.
2. Fund II has a co-invest structure with one onshore fund based in India and one offshore Fund based in Mauritius.
3. AUM is taken as the sum of both unrealised (fair market value) and realised value of portfolio and is inclusive of fees and expenses.
4. There have been no exits from Fund II yet thus there are no distributions.
5. All financial data is as of 31st March 2024.

Somerset's Portfolio Performance

Revenue CAGR for Fund I Portfolio Companies- **26%**

Revenue CAGR for Fund II Portfolio Companies- **14%**

Total Capital Invested Across Funds (USD 83 Mn/ INR 6090 Mn)



1. CAGR calculations for Fund I include- Ujala Cygnus, Krsnaa Diagnostics and Hexagon Nutrition.
2. CAGR Calculations for Fund II include all Fund II portfolio companies.
3. All financial data is as of 31st March 2024.

Fund Highlights - Media and Recognition



Somerset received the Sustainability Impact Award 2023 at the Sustainability Summit & Awards 2023 organised by UBS Forums Pvt. Ltd. Presented by IBM.



Somerset participated in the ESG programme held at Indian Institute for Management, Ahmedabad curated along with NIIF (National Investment and Infrastructure Fund).



Ramesh Kannan, Partner at Somerset Indus Capital Partners, participated as a distinguished Key Speaker at the 11th Elets Healthcare Innovation Summit and Awards.



Somerset participated in the CFO Summit organized by NIIF



Somerset receives the NIIF Health and Safety Award on behalf of its portfolio company, Emil Pharmaceutical Industries.



Somerset recognised by the IVCA under 'Fund in Focus' covering Somerset's investment thesis and the resilient and expanding healthcare sector, driven by a growing population in need of quality care.



Zulfikar Trivedi, CFO- Somerset Indus Capital Partners, attends the PE-VC CFO Association event held at Alibag, Maharashtra.

Portfolio at a Glance

FUND II



APEX HOSPITALS™



is a long-standing tertiary care hospital organization offering top-notch specialist care in both surgical and non-surgical modalities. It is a multi-specialty hospital with units in Malviya Nagar, Mansarovar, Sawai Madhopur, Jhunjhunu and Bikaner. It is very strong in Critical care and has one of the best ICU care in the State of Rajasthan.



Impact Themes

**Accessibility - Depth;
Affordability**



Vision

To deliver quality-conscious and technology-driven contemporary healthcare across segments.



Investment

**USD 4 Mn |
INR 250 Mn**
Investment
Date: May 2019



Status

Active Portfolio



— NEXT GenWorks —
Defining tomorrow, *today*.



is the largest Pan-India medical technology distribution platform, based in Bengaluru, powered by digital technology, offering goods, services, and solutions in the fields of maternity care, newborn care, imaging, cardiology, occupational therapy, critical care, oncology, and IVD. Genworks is an initiative by GE Healthcare in India for empowering healthcare professionals operating in the Tier II and Tier III districts to deliver better medical facilities and diagnostics while keeping things affordable.



Impact Themes

**Accessibility - Reach;
Affordability**



Vision

Aligning with the needs of every hospital and clinic and understanding their ecosystem to structure affordable solutions



Investment

**USD 11 Mn |
INR 831 Mn**
Investment Date:
May 2019



Status

Active Portfolio



Globela Pharma Pvt. Ltd.



has experience in producing high-quality semi-finished, final dosage formulations, and pharmaceutical active ingredient goods. Its therapeutic areas include oncology, anti-infectives, gastro, CVS, and others. The Gujarat based company majorly caters to the needs of the Rest of the World (ROW) market, India, Africa, Asia, Latin America and Middle East and is expanding to regulated markets.



Impact Themes

Accessibility - Scale & Depth, Quality



Vision

We believe that everyone should have the opportunity to access top-notch healthcare, and we are committed to making that a reality




Investment

USD 9 Mn | INR 697 Mn
Investment Date: September 2021



Status

Active Portfolio



is one of the first tertiary care corporate hospitals. It is a large multi-specialty hospital chain with a focus on oncology platforms across all locations. It is the largest multi-specialty hospital chain in Gujarat with 6 hospitals, with a focus on oncology platforms across all locations: Ahmedabad: 2 units, Vadodara: 2 units, Rajkot: 1 unit; Gandhidham: 1 unit.



Impact Themes

Accessibility - Depth; Job Creation



Vision

To be your trusted health partner by always putting the patient and community first



Investment

USD 6 Mn | INR 500 Mn
Investment Date: June 2022



Status

Active Portfolio



is a Mumbai based company that focuses on manufacturing and selling of Pharmaceutical Formulations for Multinational Corporations for over 30+ years. Their products have reached most international markets in South Central America (Chile, Peru, Venezuela, Suriname, El Salvador, Ecuador, Panama, etc.), African Countries (Nigeria, Ghana, South Africa, etc.), Southeast Asian Countries (Vietnam, Sri Lanka, Myanmar, Malaysia, Philippines, etc.) and some CIS nations.

Impact Themes
Accessibility - Scale & Depth; Affordability

Vision
 To provide excellent quality services to customers.

Investment
USD 11 Mn | INR 897 Mn
 Investment Date: April 2023

Status
 Active Portfolio



is a Bengaluru based wholly owned subsidiary of Natural Capsules Limited, foraying into the API Business.. The Company has won a PLI scheme for manufacturing of 3 products: Prednisolone & derivative salts, Betamethasone & derivative salts and Dexamethasone & derivative salts.

Impact Themes
Innovation

Vision
 to be a global leader in the steroidal and hormonal API manufacturing sector, renowned for excellence and innovation

Investment
USD 9 Mn | INR 750 Mn
 Investment Date: June 2023

Status
 Active Portfolio



is a Mumbai based pharmaceutical sustainable packaging player offering holistic solutions that yield industry-leading performance. Its product portfolio includes Cartons, Leaflets, Labels, and Foils.

Impact Themes
Quality

Vision
 To be the world's most preferred packaging company.

Investment
USD 8 Mn | INR 700 Mn
 Investment Date: February 2024

Status
 Active Portfolio

FUND I

Sandor



pioneers point-of-care products and distributes specialty pharmaceuticals, diagnostics, and medical devices nationwide, with a focus on critical care and dialysis services¹.

Impact Themes
Accessibility - Reach, Quality

Vision
 Mastering all aspects of healthcare distribution for products and services

Investment
USD 2 Mn | INR 105 Mn
 Investment Date: May 2011

Status
 Exited to a Larger PE fund



offers integrated multispecialty and diagnostic services, including pathology labs, preventive health checkups, specialist & super specialist consultation, blood tests, and corporate services.

Impact Themes
Affordability, Quality

Vision
 To provide 'Quality' medical care in a branded, cost-effective setting using standardized ambience and medical practices

Investment
USD 3 Mn | INR 150 Mn
 Investment Date: July 2012

Status
 Exited to a Strategic Investor

¹Sandor Medicais # Includes carve-out Sparsh Nephro (makes dialysis treatment accessible to kidney failure patients across India and South East Asia)



was established by a group of highly skilled doctors in 2011 with the vision of opening tertiary care centers across North India. Cygnus is a multi-specialty chain offering both elective and emergency surgeries.



Impact Themes
Accessibility - Depth, Affordability

Vision
 Creating a value based inclusive healthcare brand for tier 2 and tier 3 communities by providing quality care with emphasis on affordability

Investment
USD 5 Mn | INR 308 Mn
 Investment Date: March 2013

Status
 Partial Exit: To a Strategic Investor;
 Full Exit: To a Larger PE Fund



designs and manufactures advanced radiology and imaging technologies, including X-ray, Digital Radiography, and mobile radiology systems, with a focus on telemedicine and home health solutions.²



Impact Themes
Accessibility - Reach, Quality

Vision
 To deliver exceptional value through our products and services

Investment
USD 3 Mn | INR 184 Mn
 Investment Date: February 2014

Status
 Exited to a Strategic Investor



operates India's largest chain of NABL and NABH accredited diagnostic centers in PPP format that provide a combination of radiology and pathology services pan- India.



Impact Themes
Accessibility - Scale, Affordability

Vision
 Peoples preferred partner in improving lives

Investment
USD 5 Mn | INR 300 Mn
 Investment Date: July 2015

Status
 Partial Exit via IPO- Public Market; Full Exit via Public Market

²Prognosis Medical Systems # Includes carve-outs Prognosis Healthcare (A Tele-Medicine Solutions' Company which provides tools that integrate medical devices with cloud-based technologies.) and Chayagraphics (Medical imaging consumables distributor)



is India's first exclusive manufacturer of dialysis devices, offering a range of renal care consumables, including dialyzers, bloodline sets, AV fistula needles, and catheters. Their products, branded under Pristine and Curum, also cover critical care, cardiology, and diagnostics.

Impact Themes
Accessibility - Reach

Vision
Improving quality of life for a better tomorrow

Investment
USD 3 Mn | INR 170 Mn
Investment Date:
November 2015

Status
Active Portfolio



HEXAGON NUTRITION®
Nutritionally Yours...



creates and manufactures nutritional supplements for clients in India and abroad. The business produces and sells micronutrient premixes, ready-to-use therapeutic foods, lipid-based nutrient supplements, and ready to-use clinical nutrition solutions.

Impact Themes
Quality, Innovation

Vision
To be synonymous with complete nutraceutical solutions

Investment
USD 4 Mn | INR 249 Mn
Investment Date:
November 2016

Status
Active Portfolio

Portfolio Highlights - Awards and Accreditations




Apex Hospitals-Ranked as the 5th rank among the Best Super specialty Hospitals in Jaipur by Outlook Health- Best Hospitals Ranking 2023.



Sterling Hospitals has been conferred the 'Hospital Chain of the Year- West' by ET HealthWorld



Globea's Alignment with vision of 'One Earth One Health'





The Genworks Health and COMEN partnership revolutionizes healthcare, advancing innovation and efficiency to enhance patient outcomes in critical situations.



Dr. Simmardeep S. Gill, MD & CEO of Sterling Hospitals, has been named one of India's Most Influential Healthcare Leaders 2024.




Printmann Group has been ranked 8th in Printweek's Power 100, recognizing their leadership and dedication to excellence in the print and packaging industry.



IMPACT AT SOMERSET



Impact at a Glance




Note: The metrics presented above include all seven (7) active portfolio companies of Fund II and only three (3) portfolio companies of Fund I (Krsnaa Diagnostics, Ujala Cygnus, Hexagon Nutrition)

¹Aspirational Districts are districts in India that are affected by poor socio-economic indicators. They are the most underdeveloped districts of India as identified by NITI Aayog.

Impact by Portfolio Companies

	Total	Fund II						Fund I			
Accessibility											
Scale: Number of Customers/ Patients served	67 Mn	0.4 Mn	9 Mn	9 Mn	0.2 Mn	30 Mn			0.7 Mn	15 Mn	1 Mn
Reach: Number of aspirational districts product/ services provided in India	103	5	103		2				15		
Depth: No. of patients with life threatening diseases covered	766,653	31,979		136,569	47,935	541,164	Yet to be commissioned.	NA	9,006		
Depth: Proportion of production volume treating life threatening diseases	20%			18%		42%					
Affordability											
Direct/ Indirect revenue from Ayushman Bharat & other govt. schemes	USD 227 Mn	USD 14 Mn	USD 119 Mn		USD 14 Mn		Yet to be commissioned.	NA	USD 32 Mn	USD 47 Mn	
Number of patients treated under Government Schemes	297,565	192,994			39,830		Yet to be commissioned.	NA	64,741		
Number of Below Poverty Line (BPL) patients	1,02,870	32,152			39,614		Yet to be commissioned.	NA	31,104		



	Total	Fund II						Fund I			
Job Creation											
Number of new hires during the reporting period	5,355	380	140	169	873	49	48	37	1,450	2,169	40
Proportion of women in workforce	26%	26%	18%	21%	41%	33%	12%	5%	42%	49%	17%
Number of direct jobs	13,293	987	397	414	1,522	205	71	289	4,106	5,052	250
Number of Indirect jobs	2,108	252	55	60	704	195	226	95	173	0	348
Quality & Innovation											
Investment in technological advancements	USD 0.7 Mn (INR 60 Mn)			USD 0.24 Mn (INR 20 Mn)		USD 0.5 Mn (INR 40 Mn)					
Investment in R&D	USD 0.2 Mn (INR 15 Mn)						USD 0.2 Mn (INR 15 Mn)				
Quality certification	NABH, ISO 14001, ISO, FDCA-India, WHO GMP, EU GMP, ISO 9001:2000, ISO 9001, BRCGS, Sedex and USDMF.	NABH Accredited		EU GMP, WHO GMP, ISO 9000	NABH Accredited	EU GMP (in process), WHO GMP	Quality Mgmt. System, GMP	ISO 9001, BRCGS, Sedex, USDMF	NABH Accredited	NABH & NABL Accredited	GMP, FSSC, ISO, BRC-GS and NABL

Enabling Affordability via Ayushman Bharat and Other State Schemes

Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), launched under the National Health Policy 2017, is a cornerstone in India’s pursuit of Universal Health Coverage (UHC), targeting the most vulnerable populations.

Annual coverage of
USD 6,000 (INR 0.50 Mn)
per family



~120 Mn
poor families qualify

Reaching
~550 Mn
individuals (39% of India’s total
population of 1.4 Bn people)

Somerset, aligned with the goals of Ayushman Bharat, has ensured that its portfolio hospitals—Ujala Cygnus, Apex Hospitals, and Sterling Hospitals—actively contribute to this transformative healthcare initiative. These hospitals have been pivotal in making quality healthcare accessible and affordable to millions, with a significant portion of their payor mix coming from Ayushman Bharat and allied government schemes:

Somerset’s strategic alignment with Ayushman Bharat has not only expanded healthcare access but also ensured that quality care is affordable for those who need it most. Through these efforts, Somerset Fund continues to make a significant impact on the journey toward achieving Universal Health Coverage in India.

% of total revenue generated from Ayushman Bharat and Other State Schemes:



Impact Assessment, Mapping & Quantification

Frameworks Mapped in Investment Decision



Operating Principles for Impact Management



International Labour Organisation



International Finance Corporation - Performance Standards



United Nations Principles for Responsible Investment

Frameworks Mapped in Impact and ESG



GIIN's IRIS+



Sustainable Development Goals



Global Reporting Initiative





Sustainability Accounting Standards Board


Impact Framework Map








Somerset’s integration of impact assessment in their investment appraisal considers IRIS+ as the main impact framework also aligning with other standards such as SDG’S, SASB and SFDR.



Accessibility

Frameworks	IRIS+	SASB	SDG
No. of Customers/Patients served	PI7191 PI5743 PI3902 PI5060	HC-DY 000.B	
Number of patients treated under government scheme		HC-DY-240a.1.2 (2.2)	
Number of BPL Patients			 
No. of caregiver professionals with current licenses or certifications	OI4919 OI5323	HC-DY-330a.2.1 (1.1)	  
Disease/Condition Addressed	PI1533	HC-DY-450a.1.2.2	
Type of Care	PI1017	HC-DY-000.A	

Frameworks	IRIS+	SASB	SDG
% of revenue from distribution of product/ services in aspirational districts in India			
% of revenue derived from distribution of products in LMIC (low & middle income) countries			  
% of equipment sales in terms of volume and value to nursing homes and small hospitals (%)			 
<div data-bbox="96 715 215 831" data-label="Image"> </div> <div data-bbox="232 740 497 804" data-label="Section-Header"> <h3>Affordability</h3> </div> Total Cost saving of customer per medical visit (INR)	PI1748		
Number of generic drugs manufactured & sold			
<ul style="list-style-type: none"> Number of Customers/Patients served* Number of patients treated under government scheme* Number of BPL Patients* (*These KPIs are common for Accessibility and Affordability.)	PI7191 PI5743 PI3902 PI5060	HC-DY 000.B HC-DY-240a.1. 2 (2.2)	  

Frameworks	IRIS+	SASB	SDG
 <p>Job Creation</p> <p>Numbers of Job Created</p>	<p>OI4919 OI5323</p>		
<p>Proportion of women in workforce</p>			 
<p>Proportion of differently abled employees</p>			 
 <p>Quality</p> <p>Quality Assurance Mechanism</p>	<p>PI3863</p>	<p>HC-DY-250</p>	
 <p>Innovation</p> <p>% investment in R&D</p> <p>New products & services developed/submitted/registered</p> <p>Amount of investment made in digital technology</p> <p>No. of patents received during reporting period</p>			  

IMPACT THEMES

- Accessibility
- Affordability
- Job Creation
- Quality and Innovation



Accessibility

Accessibility in healthcare is a fundamental aspect of providing equitable and inclusive services to all individuals, regardless of their physical, sensory, cognitive, or linguistic abilities. Accessibility determines the extent to which sustainable practices and resources can be embraced by individuals, communities, and businesses. Sustainable development itself aims to meet the needs of the present generation without compromising the ability of future generations to meet their own needs, so to ensure the initiative is sustainable it must be accessible for all.

- Scale No. of lives touched: 67 Mn
- Reach 103 of 112 Aspirational Districts covered in India
- Reach 700 of 788 districts in India covered
- Depth 0.8 Mn Patients with life threatening diseases served



Apex Hospitals

● Scale ● Reach

Provides healthcare in underserved Tier II and Tier III cities of Rajasthan, such as Sawai Madhupur and Jhunjhunu districts ensuring accessibility to all. The hospital chain also provides treatment under various government healthcare schemes such as Ayushman Bharat, Central Govt. Health Scheme, Ex-servicemen Contributory Health Scheme, ESIC, and State Government Health Schemes to ensure accessibility to healthcare facilities irrespective of the sensory, linguistic, cognitive and physical state.



Number of patients treated (OPD) 0.03 Mn

Number of caregiver professionals ~650+

Genworks Health

Has expanded its product availability to customers in Tier II and Tier III cities in India, significantly increasing accessibility in remote areas and impacting a large number of lives. The equipment installed has benefited numerous patients across India.



Number of establishments operating Genworks supplied equipment 5000

Globela Pharma

Feels that drugs are to be accessible as per the region's requirement while maintaining global standards as it is a form of need in today's world. This ideology helps them cater to low and middle-income countries, as the prices are set after looking at various factors like competitors' price, region, product durability and production cost, thus giving importance to the economic viability of their end consumers to make it available with better quality and a competitive price as compared to the peers making it accessible for all. The organization has dispatched items through a tender process in India, and the government has distributed them in Tier II and Tier III cities, describing the organization's initiatives towards making its products or services accessible to underprivileged or low-income groups/BPL families.



No. of generic drugs manufactured and sold 350

● Scale ● Reach



“

At Globela, we believe that quality healthcare is a fundamental right. We are committed to making it accessible by offering affordable medicines that meet European GMP standards. Our high-quality products serve not only India but also regions across Africa and the Middle East.

Priyank Vagashia
COO, Globela Pharma

”

Sterling Hospitals

Offers a variety of medical facilities with subsidized patient financing programs to ensure that healthcare facilities are easily accessible. The targeted areas include Tier IV cities, focusing on being the first to provide healthcare facilities. Sterling Hospitals conducted health checkup camps and Outreach Outpatient services in locations with limited access to healthcare, providing these services to all categories of the population, including low-income groups and BPL families.

Number of patients treated (IPD) **0.04 Mn**

Number of caregiver professionals **~1,500**



Emil Pharmaceutical Industries

has the technical know-how for formulations across 12 therapeutic categories. Their products have reached most international markets in South, and Central America like (Chile, Peru, Venezuela, Suriname, El Salvador, Ecuador, Panama and others), African Countries (like Nigeria, Ghana, South Africa and others), Southeast Asian Countries (like Vietnam, Sri Lanka, Myanmar, Malaysia, Philippines and others) and some CIS nations. The product is designed to make it accessible for lower-income countries.

Number of new products, and services developed during the reporting period **4**

No. of new molecules being developed/under trials **4**

No. of products that have been submitted to health department for approval **125**



Natural Biogenex

● Scale ● Reach

A leading innovator in biotechnology solutions, underscores its dedication to making advanced healthcare accessible to a broader population. Its comprehensive approach to accessibility ensures that cutting-edge technological advancements, from genomic therapies to personalized medicine, are available to all individuals, regardless of their socio-economic status or geographical location. By partnering with local health providers and leveraging telemedicine platforms, the company has extended its reach to remote and underserved areas, facilitating access to breakthrough treatments.

New product launches 21

No. of new molecules being developed/under trials 3

No. of products that have been submitted to health department for approval 2



Printmann Offset

Has prioritized the development and implementation of accessible features across its products and services. This includes creating braille-compatible printing options, providing large print formats for individuals with visual impairments, and ensuring that all digital interfaces are fully navigable by screen readers and other assistive technologies. Additionally, the customer service team has been extensively trained to support individuals with diverse needs, ensuring a seamless experience for all clients.

Number of new products, and services developed during the reporting period 1



Case Study: Access - Reach

Critical Care Hope E-ICU

A Digital Health Ecosystem Enabler, An initiative of Apex Hospitals, Rajasthan




Critical Care Hope, an initiative by Apex Hospitals in Rajasthan, is making significant strides in the digital health ecosystem, particularly in the realm of critical care. With a commitment to advancing healthcare excellence, the initiative has already completed 32,000 consultations, providing vital medical attention to a broad range of patients. It has effectively treated 2,200 critical patients through both invasive and non-invasive methods, and delivered 850 super-specialty consultations, underscoring its dedication to specialized care and improved patient outcomes.

In recognition of its impactful work, Critical Care Hope has been awarded a grant of USD 0.4 Mn USAID/SAMRIDH. This grant will be instrumental in expanding its services, allowing the initiative to establish 12 full-stack ICUs. These ICUs will be fully managed and operated by Critical Care Hope, further enhancing its capacity to deliver high-quality critical care. This expansion not only reinforces the initiative's role as a leader in critical healthcare but also extends its ability to serve even more patients in need, ensuring that many others will benefit from its expert-driven, comprehensive care solutions.



Pillars of Critical Care Hope Initiative



Critical Care Hope e-ICU



In India, Intensive Care Units (ICUs) are heavily concentrated in urban centers, with only 6.8 beds per 100,000 people and fewer than 5,000 trained intensivists. Apex Hospitals has tackled this challenge with their Health Outcome Focused Prevention and Evaluation System (HOPES) 365*24*7.

This innovative initiative brings advanced critical care to Tier II and Tier III cities by connecting remote hospitals with expert intensivists through e-ICU technology. By utilizing HOPES command centers, Apex Hospitals enables local doctors to provide high-level care on-site, reducing the need for patient transfers and enhancing community healthcare.

The e-ICU model has significantly improved accessibility and patient outcomes in underserved regions and has been highlighted by filmmaker Mikey Kay for its impact on healthcare delivery in India.



Economic Impact: Case Study from Bharatpur

The tangible economic benefits realized by patients through our association in Bharatpur.

Factors	If patient needs to travel to Tier-I city	If the patient is treated in their district/hometown
Average travel distance	275 KM	40 Km
Average travel cost (Rs. 30 Per KM)	₹ 16,500	Nil
Associated Cost (If average LOS is 3 days)	₹ 5250 (Stay-1000 Per day Food-250 Per day Travel-500 Per day)	₹ 200 (Stay-0 Per day Food-0 Per day Travel-200 Per day)
Treatment cost	₹ 1,40,000	₹ 34,500
Total cost incurred	₹ 1,61,750	₹ 37,500
Cost saved by family	₹ 0	₹ 1,24,250 (Cost in Tier I - Cost in hometown)

Affordability

Affordability is a cornerstone of our mission to provide equitable healthcare services, and this year’s impact report underscores our efforts to make healthcare more accessible financially for our patients. We have implemented a variety of strategies to reduce costs without compromising on quality. This includes negotiating better rates with suppliers, optimizing operational efficiencies, and introducing sliding scale fees based on patients’ income levels. Additionally, we have expanded our financial assistance programs and partnered with community organizations to provide subsidies and support for underinsured and uninsured individuals. These initiatives have resulted in a significant decrease in out-of-pocket expenses for many of our patients, thereby reducing financial barriers to accessing necessary medical care.



Revenue generated directly and indirectly from Ayushman Bharat and other government schemes:

USD 227 Mn
(INR 18,843 Mn)



Patients treated under Ayushman Bharat and other government schemes across hospitals

0.3 Mn



Apex Hospitals

Offer affordable healthcare in Tier II and Tier III cities of Rajasthan, a chain that provides low-cost tertiary care coverage thereby contributing towards affordable healthcare. The chain also provides treatment under various non-cash government healthcare schemes such as Ayushman Bharat, Central Govt. Health Scheme, Ex-servicemen Contributory Health Scheme, ESIC, and State Govt. Health Schemes. Apex Hospitals provide individuals with services for which the bill is covered by national insurance providers, making healthcare the primary motto for the marginalized.

Proportion of patients treated under government schemes 48%

Proportion of patients provided subsidized treatment 8%



Genworks Health

Has extended its reach to districts across Tier II and Tier III markets in India and introduced telemedicine digital solutions to support government initiatives aimed at delivering quality care. Genworks has adopted a Direct-to-Customer (D2C) distribution model to enhance affordability, covering substantial portions of the Tier II and Tier III market.

Customers served in reporting period ~ 9 Mn



Globela Pharma

Exercises its belief that important drugs can be manufactured at competitive prices as per region's requirement. The prices are set after looking at various factors like competitors' price, region, product durability and production cost, thus giving importance to the economic viability of their end consumers. Company's products are distributed in government hospitals at lower rates and are available to the underprivileged or low-income groups and BPL families at concessional prices.

Number of low and middle income countries where products are distributed/sold 39



Sterling Hospitals

Is empaneled with Government schemes including Ayushman Bharat to provide quality healthcare to the communities even in the remotest areas of the country at an affordable price. Sterling Hospitals has started an initiative to create a formulary-based Pharmacy purchase to give better pricing to all patients. A significant portion is derived from this partnership, primarily serving patients from Tier 3 and Tier 4 cities.

Proportion of patients treated under government schemes 18%

Proportion of patients provided subsidized treatment 18%



“

At Sterling, we are actively advancing our healthcare initiative by deploying free health check-up camps across various parts of Gujarat. So far, we have conducted around 311 camps, impacting approximately 11,644 individuals and benefiting 39,830 people under government schemes.

Dr. Simmardeep S. Gill
MD & CEO, Sterling Hospitals


”

Case Study: Affordability - Payor

Transforming Healthcare: Providing Quality Care at Affordable Prices



Ujala Cygnus has carved a niche in the healthcare landscape by offering high-quality treatments at a fraction of the cost charged by its competitors. When comparing the pricing of key therapies, the differences are stark, particularly in cardiology, oncology, and surgical procedures.



Medical Procedures	Market Price	Ujala Cygnus Price	Discount vis-a-vis Market
Cardiology	₹1,80,000	₹50,000-₹1,00,000	44%-72%
Cardiac Surgery	₹4,00,000	₹1,25,000-₹1,75,000	56%-69%
Joint Replacement	₹2,50,000	₹50,000-₹1,00,000	60%-80%
Caesarean Section	₹2,00,000	₹10,000-₹60,000	70%-95%

Case Study: Affordability - End-Beneficiary

Krsnaa Diagnostics

Providing Quality Care at Affordable Prices



From the outset, Krsnaa Diagnostics set out to be a differentiated service provider with a strong focus on affordability. It is the largest player in the PPP (Public-Private Partnership) segment within the diagnostics sector. 65% of the company’s total revenue is derived from Public-Private Partnership (PPP) projects under the National Health Mission (NHM) that provide free diagnostic services. Leveraging their expertise in technology-driven, advanced diagnostic services, Krsnaa has partnered with public and private hospitals, medical colleges, and community healthcare centers to deliver a wide range of sophisticated diagnostics at significantly lower rates, making high-quality healthcare accessible to unserved and underserved regions across the country.

Krsnaa Diagnostics collaborates with multiple government hospitals and healthcare centers to provide affordable diagnostics services in semi-urban and rural areas across the country. Approximately two-thirds of Krsnaa Diagnostics’ revenue i.e. ~₹4,000 million, has come from government payors.

Medical Procedures	Market Price	Krsnaa Diagnostics’ Price	Discount vis-a-vis Market
CT scan	₹ 4,000	₹ 1,000- ₹1,500	63%-75%
MRI	₹ 9,000	₹ 2,250-₹2,750	69%-75%
Complete Blood Count (CBC) Test	₹ 375	₹ 150-₹200	47%-60%

Krsnaa offers radiology tests at rates 45%-60% lower than market values and pathology services at 40%-80% lower.

In FY23-24, Krsnaa Diagnostics touched the lives of 15 Mn patients and conducted a total of 44.4 Mn tests.



Case Study: Affordability - Payor

Apex Hospitals

Providing Quality Care at Affordable Prices



Apex Hospitals is committed to delivering affordable treatment in underserved Tier II and Tier III cities, such as Sawai Madhopur and Jhunjhunu in Rajasthan. By providing low-cost tertiary care, Apex Hospitals plays a crucial role in making healthcare accessible. The hospital chain also supports affordability through various non-cash government schemes, including Ayushman Bharat, Central Government Health Scheme, Ex-servicemen Contributory Health Scheme, ESIC, and State Government Health Schemes.

Apex Hospitals saw approximately ₹1,144 million in revenue from government payors for FY23-24, which accounted for 52% of the total revenue. This underscores the company's commitment to provide affordable healthcare through various government schemes.

Medical Procedures	Market Price	Apex Hospitals' Price	Discount vis-a-vis Market
Cardiology	₹ 1,80,000	₹ 1,10,000-₹1,60,000	11%-39%
Cardiac Surgery	₹ 4,00,000	₹ 1,30,000-₹1,80,000	55%-68%
Joint Replacement (Knee)	₹ 2,50,000	₹ 1,00,000-₹1,50,000	40%-60%
MRI	₹ 9,000	₹ 5,000-₹5,500	39%-44%



Critical Care Hope, a Revolutionary Initiative by Apex Hospitals

Case Study: Affordability - Number of Patients Served

GenWorks Health

Providing Quality Care at Affordable Prices



With its reach extending to 103 of the 112 aspirational districts, GenWorks is digitally powered largest pan India MedTech distribution platform offering products, services; solutions in areas of Maternal; New Born Care; Imaging; Cardiology; OT; Critical Care; Oncology; In vitro diagnostics etc. Its Tier II and III district level penetration helps provide high quality healthcare medical devices, services and consumables to nursing homes, medical colleges, trust, government and other private hospitals who in turn are supported by government schemes like Ayushman Bharat. Through these collaborations, GenWorks provides technological solutions that enhance the quality and accessibility of healthcare services in these hospitals thereby improving healthcare delivery for the underserved populations.

Genworks' Customer Base	Government scheme patients being treated (Assumed based on the customer profile and location)	Average Revenue Generated for the Year 23-24 by treating government scheme (INR Mn)
Nursing Homes (<50 Beds)	60%	1,005
Multispeciality hospitals (50-300 Beds)	40%	8,575
Medical Colleges	70%	185
Trust Hospitals	70%	150
Total		9916



Case Study: Affordability - Global Mass Market

EMIL Pharmaceutical Industries Providing Quality Care at Affordable Prices



EMIL, our portfolio company, sees its largest market in Chile, where over 55% of total revenue is generated through government-procured tenders. Additionally, 85% of EMIL's sales in Chile are allocated for final use by the government, including sales to government hospitals and clinics. In Sri Lanka, another major market for EMIL, 70% of sales are also intended for government use, with the government then distributing these products to the public.

S.no	Name of the Product	Emil's Price (per Box)	Market Pricing
1	Omeprazole	USD 2.0-3.0	Pricing of Emil's Branded alternatives is almost 1/4th of the market prices.
2	Losartan	USD 0.5-1.0	For markets like Chile & Sri Lanka, Emil is 10-15% cheaper than any competitors in government procurements.
3	Aspirin	USD 0.25-0.65	
4	Ciprofloxacin	USD 3.25-4.25	EMIL's pricing is on average 5-10% lower than alternative Generics in the market.
5	Ibuprofen + Paracetamol	USD 3.0-4.0	



Job Creation

Somerset's efforts in job creation have a broad economic impact, stimulating local economies and generating further employment opportunities. We are dedicated to diversity and inclusion, ensuring equal opportunities for all, which drives innovation and excellence. Moving forward, we remain committed to exploring new growth opportunities, investing in our employees, and contributing positively to the communities we serve, thus leading in both healthcare innovation and workforce sustainability.



Direct and indirect jobs

~15,000

8 DECENT WORK AND ECONOMIC GROWTH



Delighted to announce that
Sterling Hospitals
has been certified as a
"Great Place To Work"!



Proud to have a team that values excellence, fosters growth, and creates a positive work environment.


Fund 2

Fund 1



Indicators	Globela Pharma Pvt. Ltd.	EMIL	NATURAL BIOGENEX PVT LTD	APEX HOSPITALS	Sterling HOSPITALS	GEN WORKS	printmann	Ujala Cygnus	Krsnaa DIAGNOSTICS	HEXAGON NUTRITION
Number of direct jobs	414	205	71	987	1,522	397	289	4,106	5,052	250
Number of Indirect jobs	60	195	226	252	704	55	95	173	0	348
Total jobs	474	400	297	1,239	2,226	452	384	4,279	5,052	598

Distribution of Direct & Indirect Jobs across Fund I and Fund II




Apex Hospitals

is spearheading a significant job creation initiative in Tier 2 and Tier 3 cities across Rajasthan. By establishing state-of-the-art healthcare facilities in these regions, the hospital chain is addressing the critical need for quality medical services while simultaneously generating substantial employment opportunities. This expansion strategy is expected to create jobs for a wide range of professionals, including doctors, nurses, administrative staff, and support personnel.



Genworks Health

has made notable strides in job creation, reinforcing its role as a key player in the healthcare industry. The company has new positions in areas such as medical device manufacturing, healthcare IT, and clinical support services. This expansion reflects Genworks' commitment to improving healthcare delivery and innovation. By investing in a diverse range of talent, the company not only enhances its operational capabilities but also contributes significantly to economic growth and community development, ensuring a robust future for the healthcare sector.



Globela Pharma

has demonstrated a significant commitment to job creation, positioning itself as a vital contributor to the economy. Over the past year, Globela has expanded its workforce, creating new jobs across various sectors including clinical research, pharmaceutical manufacturing, and healthcare services. This growth not only highlights the company's dedication to enhancing patient care and advancing medical research but also underscores its role in fostering economic development.



Sterling Hospitals

has shown a strong dedication to job creation, reinforcing its leadership in the healthcare sector. The expansion in the workforce underscores the company's commitment to improving healthcare delivery and driving innovation. By investing in a talented and diverse workforce, Sterling Healthcare enhances operational capacity while making substantial contributions to economic growth and community development, paving the way for a healthier and more prosperous future.



Emil Pharmaceutical Industries

has significantly contributed to job creation, establishing itself as a pivotal force in the healthcare sector. Emil has expanded around 25% of the workforce and created jobs in the field of biopharmaceutical research, healthcare technology, and patient care services. This growth underscores the company's dedication to advancing medical innovation and improving patient outcomes. Emil not only enhances its operational excellence but also plays a crucial role in driving economic development and supporting community well-being.



Natural Biogenex

provides an excellent work and growth environment to people coming from diverse backgrounds. Each of these personnel possesses an extensive array of experience. The culture thrives on hard work, innovation, mutual respect, and a sense of accountability and responsibility. This kind of environment makes our employees feel positive and enthusiastic about what they are doing, with a clear sense of purpose, confidence in their ability to meet challenges and pride in their contribution to the company's success.



Printmann Offset

has significantly bolstered job creation efforts, marking its impact as a cornerstone in the printing industry. Printmann has expanded its workforce by 300+ employees across various departments including printing operations, design, and logistics. By investing in skilled professionals and cutting-edge technologies, Printmann not only enhances its operational capabilities but also contributes meaningfully to community prosperity.



Quality & Innovation

Quality, technology, and innovation are the cornerstones of modern healthcare, significantly impacting the delivery of patient care. High standards of quality ensure that healthcare services are safe, effective, and patient-centered, leading to improved health outcomes and patient satisfaction. By adhering to rigorous quality measures, healthcare providers can minimize errors, reduce variability in care, and enhance overall patient safety. This commitment to quality not only builds trust among patients but also drives continuous improvement within healthcare systems, ensuring that best practices are consistently followed, and that care is both efficient and equitable.

The integration of advanced technology and innovative practices further revolutionizes the healthcare landscape. Technological advancements such as electronic health records (EHRs), telemedicine, and precision medicine have transformed the way care is delivered, making it more accessible, efficient, and personalized. Innovations in medical devices, diagnostics, and treatment protocols enable early detection of diseases, more accurate diagnoses, and more effective treatments. These technological and innovative advancements not only improve patient outcomes but also optimize operational efficiencies, reduce healthcare costs, and foster a culture of continuous learning and adaptation. Together, quality, technology, and innovation form a triad that drives the evolution of healthcare, ensuring that it meets the ever-changing needs of patients and society.



Certified under industry standards

100%



Apex Hospitals

has implemented various digital solutions such as E-ICU, Tele Oncology, Tele-ECG, Tele Pathology, Tele-OPD services in satellite and network hospitals, and Tele-Medicine to enhance healthcare accessibility. The E-ICU model, featuring a 24/7 monitoring system, is designed for the remote treatment of critically ill patients, significantly reducing costs for patients and minimizing infection risks. Additionally, Apex Hospitals collaborates with IT companies and leverages Artificial Intelligence (AI) to provide swift screening and treatment solutions in remote areas, extending these services to Tier III cities.



NABH certified hospitals 100%

Genworks Health

The largest digitally powered medical technology (med-tech) distribution platform. The company follows ISO 13485: Quality Management System for Medical Device Manufacturing to ensure the medical devices meet the quality in terms of regulatory compliance. Genworks leverages its partnership with the 5C Tele Radiology platform, which facilitates the scanning of images that are transmitted to remotely located radiologists for interpretation, with the reports sent back to the primary source. Genworks aims to leverage available technology to provide affordable solutions with a focus on early health—early screening, early treatment, and early diagnosis—enabling preventive care and reducing overall healthcare costs, thus making health accessible for all.



The organization provides EVA Pro and Braster, technologies utilized for cancer screening, which are relatively uncommon in the region.

The company has 2 partnerships with academia, research institutes, and peer companies.



Genworks embraces cutting-edge technology to enhance service delivery and connectivity. From digital CRM tools to robust e-commerce capabilities, our tech-driven approach ensures efficiency and customer satisfaction. We continuously evolve our tech capabilities to meet the demands of tomorrow's challenges.

Balaji R Raghupathy

Co-founder & Senior Director, Genworks Health



Globela Pharma

Globela is a pharmaceutical manufacturer specializing in oncology, infectious diseases, digestive health, and cardiovascular treatments. Globela produces high-quality medicines and ingredients, backed by rigorous quality control and a dedicated R&D team. Committed to sustainability, the company uses clean energy and operate under ISO, FDCA-India, and WHO GMP standards.



The organization offers Ofloxacin, Norfloxacin, or Cancer review products that are currently unavailable in India.

Sterling Hospitals

all facilities have NABH accreditation and a robust internal auditing system has been established to ensure compliance with the standards. All products and equipment used in the hospitals are checked on quality parameters. A robust infection control mechanism has been implemented wherein critical areas in the hospitals are regularly monitored.



NABH certified hospitals **100%**

Emil Pharmaceutical Industries

believes in continuous quality monitoring and assurance with end-to-end Quality Management systems. The entire manufacturing operation is carried out as per GMP by qualified pharmacists and trained operators under the direct supervision of senior pharmacists. IPQC and QC check products during the entire manufacturing process per the SOP's. Their 100% in-house QC testing gives them agility, assurance, and cost advantage. Emil has held WHO-GMP certification for over two decades and obtained international regulatory accreditations from several countries. They are continuously striving for high-quality products and investing in talent and technologies to support customers.



ISO 14001 certified manufacturing units **67%**

Natural Biogenex

has continuously evolved and strengthened its efforts by consistently innovating with excellent products. With a mission to enable “Technology Assisted Business Transformation,” Natural Biogenex is committed to delivering top-notch products with a technological edge. They strictly adhere to the Quality Assurance procedures mandated by cGMP and uphold cGLP practices. The capsules manufactured meet Regulatory Authorities’ requirements, and in-house specifications are established to address customers’ changing demands for quality and machinability. Every activity is closely monitored by IPQC Inspectors to evaluate and ensure the desired product quality. Natural Biogenex follows various systems in accordance with ISO 9001:2000 to ensure that each activity is conducted systematically as per the established protocols.



The company has 4 partnerships with academia, research institutes, and peer companies.

Printmann Offset

has invested in state-of-the-art equipment and quality control systems that guarantee high-quality printing and quick turnaround. The company has built a highly skilled and committed workforce over the course of its long-running and rapidly expanding business, enabling nonstop production operations around the clock with cutting-edge software and tools available to support its operations.



The organization offers a new product, nitrosamine free blister foils, that is not currently produced or available in the country

The company has 3 partnerships with academia, research institutes, and peer companies

Case Study: Innovation

Krsnaa Diagnostics

Revolutionizing Healthcare with Tele-Radiology Innovation




Krsnaa Diagnostics is at the forefront of transforming healthcare access in India through its innovative tele-radiology platform. By connecting remote and underserved areas with expert radiologists, Krsnaa Diagnostics ensures that timely and accurate diagnoses are no longer a privilege of urban centers. This initiative is making high-quality healthcare accessible to millions who would otherwise face significant delays or barriers in receiving critical medical assessments.

At the heart of this transformation is Krsnaa Diagnostics' tele-radiology hub, a cutting-edge facility in Pune that operates around the clock. The tele-radiology hub is capable of processing large volumes of X-rays, CT scans and MRI scans round the clock over 365 days a year, including over 126,000 CT scans, over 31,500 MRIs and over 1,500,000 X-rays per month. Equipped with advanced technology and staffed by a dedicated team of

specialists, the hub serves as a lifeline for patients in distant locations. Through seamless digital connectivity, Krsnaa Diagnostics delivers real-time monitoring and precise diagnoses, enabling swift medical intervention and improving patient outcomes.

Krsnaa Diagnostics is not just reducing costs but also bridging the gap between urban and rural healthcare. By making expert radiological services available across the country, Krsnaa Diagnostics is playing a vital role in enhancing healthcare equity and ensuring that every patient, regardless of location, receives the care they need.

As Krsnaa Diagnostics continues to innovate, with plans to integrate AI and machine learning, the impact of their work is set to grow even further, solidifying their commitment to revolutionizing healthcare delivery across India.



Case Study: Quality

Globela Pharma Commitment to Quality



Globela Pharma, a multinational pharmaceutical company, plays a critical role in enhancing global healthcare through its commitment to quality. Certified by EU GMP, WHO GMP, and ISO, the company ensures that its products consistently meet the highest international standards. Operating in over 50 countries, Globela Pharma has established itself as a trusted provider of safe and effective medicines.

The company's quality control measures are central to its operations. Each product undergoes meticulous testing to ensure it meets stringent global benchmarks, guaranteeing reliability and efficacy for patients worldwide. This commitment to quality is further

supported by Globela Pharma's significant investment in research and development, which drives continuous innovation. By focusing on both quality and affordability, the company makes high-standard healthcare accessible to diverse populations, including those in underserved regions.


Globela's impact is evident in the widespread trust and reliance on its products across the globe. By ensuring that every dose of medicine it produces is of the highest quality, the company contributes significantly to improving health outcomes and making quality healthcare more accessible worldwide.



ESG AT SOMERSET



ESG at a Glance



Note: The metrics presented above include all seven (7) active portfolio companies of Fund II and three (3) portfolio companies of Fund I (Krsnaa Diagnostics, Ujala Cygnus, Hexagon Nutrition). The metrics under governance only represent the seven portfolio companies of Fund II.


ESG Philosophy and Framework Map

For Somerset, integrating ESG indicators is essential for driving impactful and sustainable investments in healthcare. By focusing on resource efficiency—such as optimizing energy use, managing water resources, and handling waste responsibly—the fund ensures minimal environmental impact and cost savings. Investing in human capital and safety enhances workforce quality and operational efficiency. Emphasizing diversity,

equity, and inclusion (DEI) within portfolio companies fosters innovation and better patient outcomes. Strong governance practices uphold transparency and ethical standards. These ESG considerations are integral to Somerset’s commitment to creating long-term value and advancing healthcare sustainability.



ESG Assessment & Mapping

Theme	Material Topics	GRI	SDGs
 ENVIRONMENT	<p>Resource Footprint</p> <p>Water & wastewater management Waste Management</p>	GRI 303, 306	  
 SOCIAL	<p>Accessibility & Affordability</p> <p>Responsible Investing Access to Finance</p>	GRI 203	  
	<p>Integrating Quality, Technology & Innovation</p> <p>Quality Products Customer satisfaction</p>	GRI 416, 418	 
	<p>Fostering Community Development & Responsibility</p> <p>Corporate Social Responsibility</p>	GRI 203, 413	    
	<p>Human Capital and Safety</p> <p>Human Capital Talent development and retention Employment Safety, Health, and Welfare</p>	GRI 401, 402, 403, 404	 
	<p>DEI - Diversity, Equality, Inclusiveness</p> <p>Diversity, Equity, and Inclusion</p>	GRI 405	  
 GOVERNANCE	<p>Governance, Risks & Controls</p> <p>Data Privacy & Security Sustainability Risks Compliance to ESG Compliance of laws and regulations</p>	GRI 2-27, 201-2	

Resource Footprint

Somerset explores the intricate relationship between healthcare excellence and environmental responsibility within its portfolio companies. By examining resources used in medical services and operations—such as energy, waste, and water—the Fund measures impacts, enhances efficiency, and aligns with sustainability goals. Through diligent management and reduction of resource footprints, Somerset reinforces its commitment to delivering sustainable healthcare solutions that benefit both individuals and the planet, promoting a collective dedication to responsible resource management for a healthier future.



Renewable energy consumption

~1,800 MWh

6 CLEAN WATER AND SANITATION




7 AFFORDABLE AND CLEAN ENERGY



12 RESPONSIBLE CONSUMPTION AND PRODUCTION



Energy Efficiency



Somerset prioritizes energy conservation and efficiency, on optimizing energy use across its operations and portfolio companies. Aiming to reduce the consumption of energy while maintaining or enhancing performance. By adopting new innovative technologies and implementing sustainable practices across its operations and portfolio companies. Somerset Fund is committed to increasing energy efficiency and promoting a greener and sustainable future.



“

By increasing the use of solar power, we harness renewable energy to reduce our carbon footprint. Our innovative steam-producing boilers help conserve electricity by minimizing the need for additional energy sources. Additionally, our plans to install a solar plant at our Greenfield site underscore our dedication to enhancing energy sustainability for a brighter, greener future.

Tushar Korday

Promoter, Emil Pharmaceutical Industries

”



“

At Printmann, sustainability is core to our energy management. We conduct annual audits to track and reduce our carbon footprint. Using transformers for efficiency and promoting 3Rs—Reduce, Re-use, Recycle—we minimize environmental impact. Recycling UV lamps under EPR and operating a biomass plant further underscore our commitment to sustainable practices.

Tejas Tanna

Jt. Managing Director, Printmann Offset

”

Globela Pharma has made substantial strides towards sustainability by installing solar panels across their plants, , with one plant meeting 60% of its energy needs through solar power, while the other achieves 80%, significantly reducing its reliance on non-renewable sources. Furthermore, they are bolstering energy efficiency by integrating advanced boilers into their operations.



Total renewable energy consumption in the current reporting period

1,600 MWh

Sterling Hospital to enhance energy efficiency, Sterling has installed an extensive array of solar panels on the rooftop of its Vadodara site. This installation enables the company to generate a significant portion of the energy required for its operations, reducing reliance on traditional energy sources and minimizing its carbon footprint.



Total renewable energy consumption in the current reporting period

~2,400 kWh

Emil Pharmaceutical Industries is harnessing the power of solar energy by installing solar power plants, while also enhancing energy efficiency by installing boilers at their plant. This allows the company to utilize renewable energy sources for its operations.



Total renewable energy consumption in the current reporting period

~23,000 kWh

Printmann Offset is actively working to reduce its dependency on conventional electricity supply for company operations by installing biomass plants that utilize organic material to generate electricity through direct combustion.



Vasai factory, approximately used 41,121 kilograms of biomass material as a renewable energy source.



Waste Management

Waste management is integral to Somerset Healthcare Fund's operations. We emphasize responsible waste disposal and recycling practices across our healthcare portfolio. Through comprehensive waste management strategies, we ensure the proper handling of medical waste, promote environmental sustainability, and support the well-being of our communities. Each company in our portfolio is registered for biomedical waste authorization and responsibly transfers hazardous waste to authorized agencies.



Fund 2

Fund 1



Indicators	Globela Pharma Pvt. Ltd.	EMIL	NATURAL BIOGENEX PVT LTD	APEX HOSPITALS	Sterling HOSPITALS	GEN WORKS NEXT GenWorks Defining tomorrow, today.	printmann	Ujala Cygnus HEALTHCARE SERVICES for your life keep... (continued)	krsnaa DIAGNOSTICS LET'S DO GOOD...	HEXAGON NUTRITION Naturally Yours...
Total solid waste generated (in MT)	5	20		47	342			132		50
Total hazardous waste generated (in MT)	21	Negligible	After commissioning	2	141			22		Negligible
Total Biomedical waste generated (in MT)	21	Negligible		14	147			79	43	Negligible
Total Waste (MT)	47	20	NA	63	630	Negligible	80.87	233	71	50
Waste generation intensity (MT/Mn USD)	1.51	0.87	Negligible	2.37	10.49	Negligible	3.73	3.35	1.00	1.40

Total Waste Generation Intensity - Fund I & Fund II



Apex Hospitals, the focus remains on actively reducing dependence on plastics across non-medical processes. This initiative underscores their commitment to promoting sustainable and responsible operations, emphasizing environmental stewardship.



Globela Pharma prioritizes sustainable practices in materials management through the adoption of lint-free cloths, promoting reusability and waste reduction. Partnerships with external recycling companies ensure responsible disposal of e-waste, aligning with Globela's commitment to environmental conservation.



Sterling Hospitals has obtained licensing for the proper disposal of biomedical waste, highlighting their dedication to safe environmental practices. A dedicated oversight role manages disposal processes, complemented by educational initiatives aimed at raising awareness of hazardous waste handling protocols.



Emil Pharmaceutical Industries implements strategic waste management practices aimed at minimizing solid waste generation. Their solid waste is responsibly managed through an Effluent Treatment Plant (ETP), ensuring compliance with government regulations for safe incineration and disposal. These efforts reflect Emil's commitment to sustainable waste management and environmental responsibility.




Natural Biogenex engages specialized waste management vendors to handle hazardous waste, ensuring compliance with pollution control board-approved landfill contracts. Their practices focus on responsible disposal to effectively mitigate environmental impact.



Printmann Offset emphasizes the principles of Reduce, Reuse, Recycle (3Rs) in its operations, particularly in the recycling of UV lamps essential to printing processes. Adherence to Extended Producer Responsibility (EPR) regulations ensures responsible disposal practices for environmental sustainability.




Water & Wastewater management



According to the FICCI, groundwater is the second largest source of water for industries in India, following surface water. It is particularly relied upon when surface water is either scarce or contaminated. Manufacturing complexes use groundwater for their operations. Given the significant water usage, there are opportunities to reduce consumption and optimize resource utilization. Water conservation involves implementing policies, strategies, and operations that aim to manage water sustainably and reduce overall usage.

Water conservation fundamentally involves reducing water usage and reusing wastewater. It encompasses any actions that lead to a decrease in water loss, consumption, or waste. In the healthcare sector, water is primarily used for cooling systems, plumbing fixtures, landscaping, and medical procedure rinses. As a Fund, we ensure our portfolio companies utilize water resources efficiently and promote a culture of water conservation within the community. We conduct regular inspections across all portfolio companies to address issues such as leaking taps, pipelines, overflowing tanks, and faulty tanks.



At Natural Biogenex, we are committed to effective water management. Our Effluent Treatment Plants (ETP) are set to begin operations, ensuring the treatment and safe discharge of wastewater. Furthermore, the upcoming Zero Liquid Discharge (ZLD) plant will enhance our efforts by completely recycling and reusing water, aligning with our goal of sustainable water use.

Sunil Mundra

CEO & Managing Director, Natural Biogenex



Apex Hospitals Has adopted ETP (Effluent Treatment Plant) and STP (Sewage Treatment Plant) methodologies for wastewater treatment. The treated wastewater is then reused for mopping and gardening purposes.



Globela Pharma actively pursues wastewater treatment and water conservation initiatives, they have established an Effluent Treatment Plant (ETP). This facility is dedicated to treating water intended for domestic use, aiming to ensure that all wastewater undergoes proper treatment and recycling processes.



Sterling Hospitals has established Effluent Treatment Plants (ETP) and Sewage Treatment Plants (STP) at their Gurukul Site in Vadodara and multiple locations in Rajkot. These facilities highlight their commitment to environmental responsibility by ensuring effective wastewater treatment that meets regulatory standards at each site.



Emil Pharmaceutical Industries' Effluent Treatment Plant (ETP) carefully follows MIDC guidelines for treating wastewater, demonstrating their dedication to responsibly managing industrial effluents in an environmentally friendly manner.




Natural Biogenex is committed to environmental sustainability and is currently in the planning stages of initiating Effluent Treatment Plants (ETP) to manage and treat industrial wastewater effectively. These projects are in preparation for implementation. Additionally, Natural Biogenex is preparing to launch a Zero Liquid Discharge (ZLD) plant, designed to prevent any liquid waste from leaving their facilities, which will be operational soon.



Human capital and safety


Somerset is committed to fostering an inclusive and diverse workplace across its portfolio, recognizing our employees as invaluable assets. We prioritize their well-being by adhering to stringent regulatory standards and implementing robust POSH procedures with dedicated committees. Our focus on increasing women’s participation at all management levels underscores our commitment to equal opportunities. Furthermore, our strict no-discrimination policy ensures a supportive environment where every employee can thrive and pursue career growth without barriers.

Safety is a cornerstone at Somerset. Regular employee satisfaction surveys inform our efforts to enhance workplace conditions, supported by comprehensive grievance policies. By providing healthcare benefits and fostering a positive culture through initiatives like health insurance, subsidized amenities, and career advancement opportunities, we uphold our commitment to employee welfare and organizational excellence.



Training hours

~31,000




Fund 2

Fund 1



Indicators	Globela Pharma Pvt. Ltd.	EMIL	NATURAL BIOGENEX PVT LTD	APEX HOSPITALS	Sterling HOSPITALS	GEN WORKS	printmann	Ujala Cygnus	Krsnaa DIAGNOSTICS	HEXAGON NUTRITION
Employees trained on Health & Safety	7%	69%	27%	16%	41%	98%	2%	13%	31%	47%
Employees trained for skills and development	2%		6%	46%	40%	1%		12%	36%	7%
Employees trained on human rights		2%		57%	2%	9%		36%	60%	25%

Training of employees on ESG - Fund I & II



Apex Hospitals

The company prides itself on its commitment to safety, as evidenced by its Fire-safe certification. Utilizing advanced technology, Apex includes state-of-the-art sprinklers, smoke detectors, and ladders in its product line. Moreover, the company is proactive in implementing changes to comply with the latest industry norms, ensuring both innovation and adherence to regulatory standards.



“

At Apex, safety is our priority. We hold fire-safe certification and utilize advanced technology such as sprinklers, smoke detectors, and ladders to ensure a secure environment. Committed to continuous improvement, we implement changes in accordance with updated safety norms, safeguarding our workplace for everyone’s well-being.

Sachin Jhavar
Director, Apex Hospitals

”

Emil Pharmaceutical Industries

Comprehensive safety and skill development for all employees, whether temporary or permanent, is prioritized. Supervisors and engineers guide workers in safety practices, complemented by regular training from the HSE manager. Bi-annual POSH (Prevention of Sexual Harassment) training is offered, facilitated by an external agency, with planned soft skills and stakeholder communication sessions to ensure a well-rounded workforce.



Genworks Health

A significant portion of the workforce is dedicated to skills and development training, reflecting the company’s commitment to continuous improvement. Initiatives to enhance healthcare awareness include interactive demos, screening camps, regular hospital visits, and direct doctor engagement programs. These efforts not only promote health education but also foster a proactive approach to employee well-being within the organization.



Globela Pharma

Dedicated to enhancing workplace safety through comprehensive awareness and induction training programs, guided by a robust SOP for training. Safety Officers and Committees ensure strict adherence to safety practices, supported by regular health check-ups for all employees. Extensive hygiene training, on-job safety training, and mock drills are conducted to maintain a safe working environment. Additionally, the POSH Committee and detailed Occupational Health and Safety SOPs systematically reduce workplace hazards, preventing accidents, illnesses, and injuries.



Natural Biogenex

Provides comprehensive training covering Health and Safety (H&S), Good Manufacturing Practices (GMP), and Standard Operating Procedures (SOPs). Additionally, external personnel focus on employee mental health, supported by the POSH policy and committee. All employees undergo pre-medical and annual medical check-ups to ensure their well-being.



Printmann Offset

The well-being and safety of employees are prioritized through comprehensive annual medical checks, including pre-employment evaluations. Regular fire and mock drills are conducted to ensure preparedness for any emergency. The HSE manager leads proactive safety initiatives and training sessions, while the POSH committee fosters a secure environment for women with ongoing safety training.



Sterling Hospitals

is dedicated to fire safety. The company actively works on refining fire safety processes and guidelines. Sterling Hospitals adhere to comprehensive Occupational Health and Safety Management Procedures outlined in the ESMS Manual.



Diversity Equity and Inclusion

Somerset is dedicated to fostering diversity, equity, and inclusion (DE&I) across its portfolio, aiming to create an inclusive workplace that mirrors the diversity of our community. We value our employees as our most cherished assets, providing them with the tools and support needed to achieve their full potential. Embracing diversity and inclusion is essential not only for the current workforce but also for attracting and retaining future talent. We are actively focused on increasing women's engagement at all levels of management, ensuring equitable opportunities for career growth and leadership within our organizations.

Across all Somerset portfolio companies, strict adherence to regulatory requirements is coupled with proactive initiatives to empower a diverse workforce, fostering a safe and supportive workplace environment. Our commitment to enhancing gender diversity extends to enforcing a strict no-discrimination policy across all facilities, promoting an environment where every employee can thrive and access equal career opportunities.



Women serving in diverse roles

~6,000

5

GENDER
EQUALITY



8

DECENT WORK AND
ECONOMIC GROWTH



10

REDUCED
INEQUALITIES




Fund 2

Fund 1



Indicators	Globela Pharma Pvt. Ltd.	EMIL	NATURAL BIOGENEX PVT. LTD.	APEX HOSPITALS	Sterling HOSPITALS	GEN WORKS	printmann	Ujala Cygnus	krsnaa DIAGNOSTICS	HEXAGON NUTRITION
Women in workforce	21%	33%	12%	26%	41%	18%	5%	42%	49%	17%
New women hires	20%	41%	21%	26%	35%	1%		50%		24%
Women founders	33%	50%								
Ratio of average remuneration of women to men	0.94	0.88	0.07	0.81	1.42	0.75			0.89	0.77

Ratio of average remuneration of women to men



Apex Hospitals

Promotes inclusivity by organizing all-women shifts during regular hours, emphasizing gender equality and a discrimination-free atmosphere. Employees receive extensive awareness training to foster a gender-neutral workplace culture. The company is proud of its diverse workforce, which reflects its dedication to equal opportunities, ensuring women are well-represented among contracted staff. Moreover, the presence of women in senior leadership positions illustrates continuous efforts to advance gender equality and ensure representation across all levels of the organization.

Number of Women among C-suite

5

Women among contract workers

39%



Emil Pharmaceutical Industries

Company maintains a culture that is void of gender discrimination, with no documented incidents to date. Committees are diligently established to promptly tackle any discrimination issues that arise. The significant presence of women in the workforce underscores a strong dedication to diversity.

Women founders

50%

Women among contract workers

29%



Genworks Health

Has established a dedicated team of local staff focused on serving the Northeastern Area. With a commitment to diversity, the company proudly maintains a proportionate representation of women among its contracted workforces. This initiative not only enhances community engagement but also fosters a culture of inclusivity and equitable employment practices within the organization.

Number of Women among C-suite

3

Women among contract workers

27%



Globela Pharma

Prides itself on fostering a diverse workforce with significant female representation, maintaining a commitment to gender equality and inclusive leadership throughout its organizational culture.



Women founders 33%

Ratio of average remuneration for women to men 0.94

Women in workforce 21%

Natural Biogenex

Has taken proactive steps to enhance workplace diversity by recruiting women employees into general shifts, demonstrating a commitment to inclusivity. These initiatives promote gender diversity and contribute to a more balanced and inclusive workforce culture. By actively fostering an equitable and supportive work environment, Natural Biogenex is setting a positive example in the industry and creating opportunities for women in traditionally male-dominated sectors. This approach not only enriches the company's talent pool but also leads to improved decision-making and innovation through diverse perspectives.



Women in workforce 12%

Printmann Offset

A strong commitment to inclusivity is evident through the implementation of a strict non-discrimination policy. The company boasts a diverse workforce, particularly notable in roles involving CSR and packing activities, reflecting their inclusive hiring practices. All hiring decisions are made based on unbiased criteria, ensuring equal opportunities for all applicants. This approach not only fosters a respectful workplace culture but also enhances productivity and innovation through diverse perspectives and experiences.



Number of women employed 20

Sterling Hospitals

Committed to fostering Diversity, Equity & Inclusion through a comprehensive framework. The hospital actively monitors and aims for equitable representation, with a particular emphasis on including women among contract workers. Regular training sessions and workshops are hosted to raise awareness and implement DE&I principles, fostering a supportive and inclusive environment for all employees.



Women among contract workers

27%



Governance and Business Ethics

Somerset maintains rigorous corporate governance standards aimed at upholding professionalism, honesty, and sustainable business practices. Our code of conduct emphasizes integrity, dependability, and ethical behaviour across all aspects of our operations. Each of our Portfolio Companies adheres to robust grievance redressal systems to promptly address stakeholder concerns. We prioritize raising corporate governance benchmarks and actively engage in anti-corruption initiatives.

Compliance forms a cornerstone of our operations, encompassing anti-bribery, anti-corruption, anti-money laundering, and conflict of interest regulations. We are committed to fostering transparency and accountability, which are integral to managing Environmental, Social, and Governance (ESG) risks effectively.

As a healthcare-focused fund, safeguarding stakeholder data, especially patient information, is paramount. Our portfolio firms adhere to stringent cybersecurity protocols and employee codes of conduct to ensure the confidentiality and integrity of client data. Our Human Resources policies reinforce ethical and socially responsible behaviour among all employees.

Under our Occupational Health and Safety (OHS) policy, Somerset strives to provide safe working conditions and reasonable working hours for the health, safety, and welfare of employees, visitors, and the public. We have implemented procedures to detect and prevent money laundering and terrorist financing activities, ensuring that capital contributions originate from legitimate sources and investments are made in compliance with all legal requirements.

100% Fund II portfolio companies have an Anti-Corruption and Anti-Bribery Policy

100% Fund II portfolio companies have Employee Code of Conduct policy

100% Fund II portfolio companies have established Grievance Redress Mechanism

Business Ethics

Anti-bribery and anti-corruption policy



Somerset is committed to conducting its business operations in strict accordance with the highest moral and ethical standards as articulated in its Anti-Bribery and Anti-Corruption (ABAC) Policy. The company ensures that both its Funds and Portfolio Companies adhere rigorously to these guidelines. Somerset maintains a steadfast stance against all forms of bribery and corruption by Employees, Consultants, or Third Parties. The organization firmly prohibits any attempts to improperly influence others, whether directly or indirectly, through the solicitation, payment, or acceptance of bribes or kickbacks. This unwavering commitment underscores Somerset's dedication to upholding transparency, fairness, and ethical behaviour across all aspects of its business activities.

Anti-Money Laundering and Know Your Customer Policy



Somerset upholds business ethics and governance by implementing a robust KYC and AML policy that ensures compliance with legal standards and international regulations. This policy helps prevent money laundering and terrorist financing by setting clear guidelines for due diligence, monitoring, and reporting of suspicious activities. It requires thorough vetting of investors and Portfolio Companies, and mandates regular updates to adapt to regulatory changes, ensuring that all business dealings are legitimate and ethically sound.

Code of Ethics



Somerset aims to establish itself as a premier employer, recognizing that its workforce represents the company's future. As a knowledge-based sector, Somerset prioritizes the development, engagement, fair reward, and retention of its employees through consistent, equitable, and transparent procedures throughout their entire employment journey. Within Somerset's inclusive workplace culture, built on respect, employees are provided abundant opportunities for personal and collective growth, success, and advancement. The organization's Human Resources policy reinforces the expectation that all employees uphold responsible, socially conscious, and ethical behaviour, clearly outlining these standards. Under Somerset's Occupational Health and Safety (OHS) policy, the company is committed to providing suitable working conditions, including reasonable working hours and a safe environment. This commitment extends to safeguarding the health, safety, and welfare of employees, visitors, and the public affected by Somerset's operations, to the best of practicable standards.

Data Privacy & Security



During their tenure at Somerset, employees acknowledge that all intellectual property developed, including discoveries or inventions made within the scope of their duties and relating to Somerset's business, remains the exclusive property of Somerset. Employees are granted access to confidential information, data, business property, keys to premises, or any other business-related property or information solely for the benefit of Somerset. Confidential information encompasses all non-public data in any form pertaining to Somerset, its affiliated entities, clients, or operations. Employees are obligated to handle this information in good faith, preventing unauthorized disclosure and promptly reporting any breaches if prevention is impractical. Non-compliance with this policy may result in performance improvement proceedings, up to and including dismissal. Somerset reserves the right to pursue monetary damages or seek other remedies for breaches of confidentiality or intellectual property rights.



Grievance Redressal Mechanism	✓	✓	✓	✓	✓	✓	✓
Employee Code of Conduct	✓	✓	✓	✓	✓	✓	✓
Anti-corruption/ Anti-bribery Policy	✓	✓	✓	✓	✓	✓	✓
Women in Board of Directors	✗	✗	✓	✗	✓	✗	✗
Cyber Security Policy/ Statement	✓	✓	✓	✓	✗	✓	✓
Policy Statement on Customer Data Privacy and Integrity	✓	✓	✓	✓	✓	✓	✓

✓ Yes ✗ No

The metrics under governance only represent the seven portfolio companies of Fund II

CSR & STAKEHOLDER ENGAGEMENT



CORPORATE SOCIAL RESPONSIBILITY

Somerset maintains regular and honest contact with its stakeholders to preserve long-term relationships and understand them. Our Stakeholders vary in terms of the degree of interest, influence and control they have over a project or asset and similarly their interest and influence vary depending upon the stage of the project. Employees, investors, consumers, patients, regulatory agencies, industry organizations, vendors, suppliers, NGO partners, and community people are all touched by our actions. We maintain timely contact with our stakeholders because we believe that their perspectives aid us in strategic planning and the achievement of our business and sustainability objectives. We ensure that any essential information is communicated to our stakeholders in a transparent and timely manner. We take steps to safeguard the well-being of stakeholders who are vulnerable and marginalized because of their gender, age, ethnicity, occupation, or ability. We aim to integrate stakeholder engagement as an inclusive and continuous process.

At Somerset, we believe that our responsibility extends beyond generating returns for our investors. As a healthcare fund, we are uniquely positioned to drive positive change in society through strategic Corporate Social Responsibility (CSR) initiatives. Our approach to CSR is multifaceted, focusing on education, healthcare, and community development. By leveraging our expertise and resources, we aim to create lasting impact in these crucial areas, improving lives and fostering sustainable growth. Our CSR initiatives reflect our commitment to being responsible corporate citizens and our dedication to making a meaningful difference in the communities we serve.

Globela Pharma

Commitment to corporate social responsibility is exemplified through targeted community activities. Its initiatives focus on supporting local hospitals, improving the lives of underprivileged children, and empowering women in the communities where it operates. By addressing these critical areas, Globela strives to create meaningful, positive change and foster sustainable development in society.



Sterling Hospitals

Committed to supporting community well-being beyond healthcare. As part of its Corporate Social Responsibility initiatives, the hospital has partnered with the Akshaya Patra Foundation to support their midday meal program. This collaboration aims to combat classroom hunger and promote education by providing nutritious meals to underprivileged school children.



Emil Pharmaceutical Industries

The company demonstrates its commitment to corporate social responsibility through strategic educational investments. The company actively contributes to the advancement of higher education by making general donations to prestigious institutions, including the renowned Indian Institute of Technology (IIT) Bombay. By supporting these centers of excellence, Emil aims to foster innovation, research, and skill development, ultimately contributing to the nation's intellectual and economic growth.



Natural Biogenex

Demonstrates its commitment to corporate social responsibility through targeted community engagement initiatives. The company has conducted educational training programs, focusing on skill development and knowledge enhancement for local residents. Additionally, Natural Biogenex has actively sponsored various village-level activities in Bangalore, contributing to the social and cultural vibrancy of rural communities while fostering stronger ties with local stakeholders.



Printmann Offset

Demonstrates its commitment to corporate social responsibility through strategic initiatives that create lasting impact. The company actively supports education by providing funding through the Satya Shivam Sai Baba Foundation, enabling access to quality learning opportunities for underprivileged communities. Additionally, Printmann invests in research and development initiatives that not only drive its own innovation but also extend support to smaller companies, fostering growth and sustainability across the business ecosystem.



Stakeholder Engagement Process

Stakeholder Engagement is achieved through the following:



Identification

Determining the nature of the key stakeholders' impacts and concerns, as well as their interests and influence, and examining the effects of these on company operations



Customization

Designing suitable engagement methods that are suited to the demands of stakeholders and fulfil international standards



Prioritization

Developing systems to regularize engagement, disclose relevant information at appropriate times, obtain feedback and provide an accessible process of grievance redressal



Validation

Adopting the principles of transparency, inclusivity, and cultural appropriateness in all engagement mechanisms



Dissemination

Continuously increasing stakeholder engagement performance by sharing best practices and lessons learned throughout our core markets.




LOOKING FORWARD

From its inception, Somerset investment focus has been in businesses that reach the masses, delivering high quality healthcare products and services in Tier 2 and Tier 3 cities, reducing the burden of life-threatening diseases in underserved areas at affordable prices.

Going forward, Somerset remains committed to tackling the critical issues of accessibility and affordability in Indian healthcare. With Fund 3, we are sharpening our focus on creating meaningful impact, particularly for marginalized communities, while mapping our efforts against IMM principles.

Our impact is defined through the following metrics :



As an “ESG & Impact opportunity seeker,” we integrate Environmental, Social, and Governance (ESG) factors and impact considerations throughout our investment cycle—from selection and portfolio management to shareholder advocacy and exits. Our ESG and impact reporting framework, based on global standards ensures we remain accountable and transparent. We believe that ESG and impact are vital for long-term, sustainable value creation, benefiting not just our fund and portfolio companies, but also their employees, the environment, and society as a whole.

In FY25, we are committed to report Scope 1 and Scope 2 greenhouse gas emissions of our portfolio companies. The ball has already been set rolling and the baseline measurement will set the stage for decarbonisation strategy.

Some portfolio companies have commenced on this path using solar power, this reducing dependence on non-renewable resources. We are also deepening our focus on gender diversity, equity, and inclusion in the portfolio companies.

We recognize that the future of healthcare will be shaped by technology, and we are collaborating with our tech partners to develop AI, machine learning, and VR-based solutions that enhance healthcare availability, accessibility, and affordability.

While we have been measuring most of the above metrics, we will institutionalize more robust reporting from portfolio companies and undertake special studies to measure the depth of impact.

GLOSSARY

S.no	Abbreviation	Full Form
1	API	Active Pharmaceutical Ingredient
2	Aspirational Districts	Most under-developed districts across the country
3	AUM	Assets Under Management
4	BPL	Below Poverty Line
5	BRCGS	BRC Global Standard for Food Safety
6	CAGR	Compound Annual Growth Rate
7	CAP	College of American Pathologists
8	CIS	Commonwealth of Independent States
9	CP	Conditions Precedent
10	CS	Conditions Subsequent
11	CSR	Corporate Social Responsibility
12	E&S	Environmental and Social
13	ESAP	Environmental & Social Action Plan
14	ESG	Environment, Social and Governance
15	ESIC	Employee State Insurance Corporation
16	EU GMP	European Union
17	FDCA	Federal Food, Drug, and Cosmetic Act
18	FICCI	Federation of Indian Chambers of Commerce & Industry
19	GHG	Greenhouse Gas
20	GIIN	Global Impact Investing Network
21	GLP	Good Laboratory Practice
22	GRI	Global Reporting Initiative
23	ICU	Intensive Care Unit
24	IFC	International Finance Corporation

S.no	Abbreviation	Full Form
25	ILO	International Labour Organization
26	IMM	Impact Measurement & Monitoring
27	IPQC	Input Process Quality Control
28	ISO	International Organization for Standardization
29	IVCA	Indian Venture and Alternate Capital Association
30	LMICs	Low-to-Middle-Income Countries
31	NABH	National Accreditation Board for Hospitals & Healthcare Providers
32	NABL	National Accreditation Board for Testing and Calibration Laboratories
33	NCR	National Capital Region
34	OPIM	Operating Principles for Impact Management
35	PPP	Public Private Partnership
36	PRI	Principles for Responsible Investment
37	QC	Quality Control
38	Samridh	Sustainable Access to Markets and Resources for Innovative Delivery of Healthcare
39	SASB	Sustainability Accounting Standards Board
40	Sedex	Supplier Ethical Data Exchange
41	SIH	Somerset Indus Healthcare Fund
42	SOP	Standard Operating Procedure
43	UN SDGs	United Nations Sustainable Development Goals
44	USAID	United States Agency for International Development
45	USDMF	US Drug Master File
46	WHO GMP	World Health Organization Good Manufacturing Practices

ABOUT THE REPORT

The Report has been prepared by Somerset to provide stakeholders with information regarding its impact and sustainability efforts. The information presented in the report is based on data and sources deemed reliable by the firm; however, the accuracy, completeness, and timeliness of the information cannot be guaranteed. The report is not audited and does not constitute a certified assurance statement. The data, metrics, and information presented herein are subject to inherent limitations, including but not limited to data availability, data accuracy, and calculation methodologies. Users are encouraged to exercise their judgment and discretion when interpreting and utilizing the information provided in the report.

The report may contain forward-looking statements that reflect Somerset's current beliefs, assumptions, and expectations regarding future events, performance, or outcomes. Such statements are inherently subject to risks, uncertainties, and changes in circumstances that could cause actual results to differ materially from those expressed or implied in the forward-looking statements.

Somerset reserves the right to update, amend, or modify the report at any time without notice. The information in the report may become outdated due to changing circumstances, and the firm is under no obligation to update or maintain the accuracy of the information.



Reporting References

The report presents Somerset's impact, environmental, social, and governance parameters for the period April 1, 2023, to March 31, 2024. The report has been developed keeping in mind United Nation's Sustainable Developmental Goals for defining report content and quality. The report is also aligned with GRI standards, IRIS+ and SASB.



Reporting scope & Boundary

The scope of reporting covers Somerset's performance on various impact, environmental, social and governance parameters for its Fund 1 and Fund 2 portfolio companies. For the purpose of this report, the impact and sustainability data of Fund 1 is presented for three (3) portfolio companies i.e. Ujala Cygnus, Krsnaa Diagnostics and Hexagon Nutrition that were active investments in FY24. The impact and sustainability data for Fund 2 is presented for the entire portfolio of seven (7) companies, each of these being active investments. Wherever applicable, India is our significant location unless otherwise specified. The word 'local' refers to India, wherever applicable.



Feedback & Questions

The Impact & Sustainability Report for FY24, is both a communications tool to all our stakeholders and an operational document that assists us in informed decision-making. Any feedback or query related to this report can be communicated to Somerset's ESG Manager, Ameya Karulkar at akarulkar@somersetinduscap.com.



Knowledge Partner

Envint Services LLP ("Envint"), a sustainability and ESG services firm, has supported Somerset in developing and implementing the impact and sustainability measurement framework across Fund I and Fund II portfolio companies; ESG data collection and validation of portfolio companies; and preparation of the Impact and Sustainability Report for FY24. Envint works with a diverse set of clients in India, Europe and North America to integrate sustainability, channelize responsible investment and enable climate action. To learn more, visit www.envintglobal.com. Any feedback or query related to this report can also be communicated to Lucille Andrade (Partner at Envint) at lucille@envintglobal.com.


 Envint
Business for Better



Somerset Indus Capital Partners



Corporate Address

401, 4th Floor, Pharma Search House,
72/73, Worli Hill Estate, Dr. B.G. Kher Road
Worli, Mumbai 400018



<https://somerseinduscap.com/>



<https://www.linkedin.com/company/somerse-indus-capital-partners/>



info@somerseinduscap.com